Hyderabad Police Launches AIPowered Multilingual Complaint App Implications for Public Sector Digitalization Sebi Chief Tuhin Kanta Pandey Advocates for Bond ETFs and Tokenisation as Corporate Debt Fundraising Approaches Rs 9 Lakh Crore US Consumers Face Inflation Pressure as Holiday Weekend Spending Surges on Travel Recreation and Food Costs Medpace MEDP Faces Securities Class Action Lead Plaintiff Deadline on June 8 2026 China Emerges as Key Competitor in Humanoid Robotics Race Says Elon Musk National Retail Federation Projects 44 Growth in US Retail Sales for 2026 Kairos Pharma Ltd KAPA Q1 2026 Earnings EPS Misses Estimates Amid Ongoing ClinicalStage Operations CZR Q1 2026 Earnings WiderthanExpected Loss Weighs on Sentiment Global Self Storage Inc SELF Q4 2025 Earnings EPS Falls Short of Estimates as Revenue Details Remain Undisclosed EME Q1 2026 Earnings EPS Surges 1487 Above Estimates Stock Gains ITW Q1 2026 Earnings EPS Beats Estimates Amid Operational Strength PAYS Q1 2026 Earnings Earnings Beat Estimates as EPS Surprises to the Upside Broadstone Net Lease BNL Hovers Near 2040 Amid Modest Trading Sportradar SRAD Edges Lower Amid Tepid Volume Key Support Levels in Focus Kura Oncology KURA Slips 244 as Shares Approach Key Support Zone BioHarvest Sciences Inc BHST Edges Higher as Price Approaches Resistance After Support Test DMC Global BOOM Hovers Near Support Amid Minimal Price Movement Larimar Therapeutics LRMR Edges Lower as Stock Tests Key Support Zone PubMatic Inc PUBM Shows Resilience Price Action and Key Levels After 147 Gain LaFayette Acquisition Corp Unit LAFAU Holds Steady at 1010 as SPAC Unit Trades in Tight Range Oaktree Acquisition Corp III Life Sciences Units OACCU Slip 25 Support Levels in Focus Essent Group ESNT Retreats From Resistance Key Support Levels in Focus Ethan Allen Interiors ETD Holds Steady Near 1974 as Support and Resistance Levels Come into Focus Surging Gas Prices Disproportionately Squeeze LowerIncome Households New York Fed Study Suggests TD Q1 2026 Earnings EPS Beat Bolsters Investor Confidence Amidst Ongoing Regulatory Challenges Gain Therapeutics GANX Surges 147 as Volume Picks Up Testing Resistance at 213